UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 29

Sortiert nach

Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis

Journal of allergy and clinical immunology, 2014-04, Vol.133 (4), p.1032-1040

2014

Volltextzugriff (PDF)

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

The Lancet (British edition), 2008-05, Vol.371 (9625), p.1665-1674

2008

Volltextzugriff (PDF)

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

Journal of the American Academy of Dermatology, 2008, Vol.58 (1), p.106-115

2008

Volltextzugriff (PDF)

A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis

Journal of the American Academy of Dermatology, 2014-12, Vol.71 (6), p.1176-1182

2014

Volltextzugriff (PDF)

Humanized anti–IFN-γ (HuZAF) in the treatment of psoriasis

Journal of allergy and clinical immunology, 2015-02, Vol.135 (2), p.553-556.e3

2015

Volltextzugriff (PDF)

Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis

Journal of the American Academy of Dermatology, 2010-09, Vol.63 (3), p.448-456

2010

Volltextzugriff (PDF)

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial

JAMA dermatology (Chicago, Ill.), 2020-06, Vol.156 (6), p.649

2020

Volltextzugriff (PDF)

Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy

Journal of the American Academy of Dermatology, 2019-09, Vol.81 (3), p.775-804

2019

Volltextzugriff (PDF)

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions

Journal of the American Academy of Dermatology, 2011-07, Vol.65 (1), p.137-174

2011

Volltextzugriff (PDF)

Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a

Seminars in cutaneous medicine and surgery, 2016-06, Vol.35 (4 Suppl 4), p.S74-S77

Leonardi, Craig L

2016

Volltextzugriff (PDF)

Small Molecules for Psoriasis

Seminars in cutaneous medicine and surgery, 2016-06, Vol.35 (4 Suppl 4), p.S65-S66

Leonardi, Craig L

2016

Volltextzugriff (PDF)

Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS)

BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 2021-03, Vol.35 (2), p.229-238

2021

Volltextzugriff (PDF)

Therapeutic development in psoriasis

Seminars in cutaneous medicine and surgery, 2014-06, Vol.33 (4 Suppl), p.S69-S72

2014

Volltextzugriff (PDF)

Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study

Journal of drugs in dermatology, 2013-08, Vol.12 (8), p.888

2013

Volltextzugriff (PDF)

Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: Updated results from an ongoing trial

Journal of the American Academy of Dermatology, 2006-04, Vol.54 (4), p.S154-S163

2006

Volltextzugriff (PDF)

Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy

The Journal of dermatological treatment, 2006, Vol.17 (1), p.9-17

2006

Volltextzugriff (PDF)

Impact of adalimumab treatment on patient-reported outcomes: Results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis

The Journal of dermatological treatment, 2007, Vol.18 (6), p.341-350

2007

Volltextzugriff (PDF)

Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis

Journal of the American Academy of Dermatology, 2006-04, Vol.54 (4), p.S164-S170

2006

Volltextzugriff (PDF)

Current concepts and review of efalizumab in the treatment of psoriasis

Dermatologic clinics, 2004-10, Vol.22 (4), p.427-435

Leonardi, Craig L.

2004

Volltextzugriff (PDF)

Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis

Journal of drugs in dermatology, 2004-11, Vol.3 (6), p.614

2004

Volltextzugriff (PDF)

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

The Lancet (British edition), 2015-08, Vol.386 (9993), p.541-551

2015

Volltextzugriff (PDF)

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

The Lancet (British edition), 2013-08, Vol.382 (9894), p.780-789

2013

Volltextzugriff (PDF)

Clinical efficacy of efalizumab in patients with chronic plaque psoriasis : Results from three randomized placebo-controlled. Phase III trials: Part I

Journal of cutaneous medicine and surgery, 2005-12, Vol.9 (6), p.303-312

2005

Volltextzugriff (PDF)

New Therapies for Psoriasis

Seminars in cutaneous medicine and surgery, 2016-06, Vol.35 (4 Suppl 4), p.S71-S73

Leonardi, Craig L

2016

Volltextzugriff (PDF)

Overview of psoriasis: update on current and emerging treatment options

Managed care, 2003-05, Vol.12 (5 Suppl), p.3

Leonardi, Craig L

2003

Volltextzugriff (PDF)

1 – 25 von 29

Suche als RSS-Feed

Aktive Filter

ThemaTreatment Outcome

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(20)

Publikationsform

Artikel
(28)
magazinearticle
(1)

Sprache

Englisch
(29)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(29)
Life Sciences & Biomedicine
(24)
Psoriasis - Drug Therapy
(24)
Science & Technology
(24)
Dermatology
(22)
Female
(19)
Male
(19)
Adult
(16)
Middle Aged
(16)
Psoriasis
(15)
Antibodies, Monoclonal - Adverse Effects
(14)
Severity Of Illness Index
(14)
Double-Blind Method
(13)
Antibodies, Monoclonal - Administration & Dosage
(12)
Antibodies, Monoclonal - Therapeutic Use
(12)
Biological And Medical Sciences
(11)
Medical Sciences
(11)
Psoriasis. Parapsoriasis. Lichen
(11)
Cytokines
(7)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis

Humanized anti–IFN-γ (HuZAF) in the treatment of psoriasis

Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial

Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions

Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a

Small Molecules for Psoriasis

Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS)

Therapeutic development in psoriasis

Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study

Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: Updated results from an ongoing trial

Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy

Impact of adalimumab treatment on patient-reported outcomes: Results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis

Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis

Current concepts and review of efalizumab in the treatment of psoriasis

Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

Clinical efficacy of efalizumab in patients with chronic plaque psoriasis : Results from three randomized placebo-controlled. Phase III trials: Part I

New Therapies for Psoriasis

Overview of psoriasis: update on current and emerging treatment options

Aktive Filter

Suchergebnisse filtern